Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Settles Dispute over Lab Sale


Rosetta Genomics said this week that it has settled a dispute with Sanra Laboratories in connection with Rosetta’s sale of Parkway Laboratories to Sanra in 2009.

As reported by Gene Silencing News, Rosetta bought Parkway for $2.9 million in 2008 in order to pick up the expertise and infrastructure needed to begin marketing its line of microRNA-based diagnostics (GSN 6/12/2008).

Rosetta used Parkway’s CLIA certification to establish its own CLIA-certified lab where it performs its miRNA tests, and sold off Parkway to Sanra the next year for up to $2.5 million, payable over six years as a fixed percentage of revenues (GSN 5/21/2009).

This week, Rosetta said that Sanra has agreed to use its “best efforts” to pay Rosetta $625,000, in addition to all sums previously paid, to meet obligations under a stock-purchase deal inked in conjunction with the Parkway sale.

Additional terms of the settlement were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.